Aiforia Technologies

The new technology promises to accelerate the development of AI models and improve their performance, supporting the expansion of the company's product portfolio.

14:40

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

31:45

Jukka Tapaninen, CEO, talks about medical software company Aiforia as an investment.

The share issue was expected, although it took place slightly earlier than we predicted, was smaller, and at a slightly lower valuation.

Welcome to follow Life Science Night on Tuesday, December 9 at 3:30 pm EET on inderesTV.

Aiforia's implemented cost savings will help manage its financing needs in the coming years while the turnaround of a strong customer base into accelerating revenue growth will take time.

The company intends to ensure the achievement of its mid-term strategic goals through adjustment measures, which, in our view, means turning the business profitable by 2027.

Aiforia will at least challenge and potentially replace its competitor IBEX's solutions in the customer relationship.

This is the first completed deployment of the framework agreement Aiforia announced last year. The release supports our current view that the transition of the company's key, already won, customer accounts to a clear volume phase would take place in 2026-2028, and thus does not cause pressure to change our forecasts.